

William Vainchenker

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9433798/william-vainchenker-publications-by-citations.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

154
papers

15,307
citations

65
h-index

123
g-index

164
ext. papers

17,194
ext. citations

5.9
avg, IF

6.04
L-index

#	Paper	IF	Citations
154	A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. <i>Nature</i> , 2005 , 434, 1144-8	50.4	2769
153	Mutation in TET2 in myeloid cancers. <i>New England Journal of Medicine</i> , 2009 , 360, 2289-301	59.2	1376
152	TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. <i>Cancer Cell</i> , 2011 , 20, 25-38	24.3	653
151	Prognostic score including gene mutations in chronic myelomonocytic leukemia. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2428-36	2.2	373
150	JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. <i>Blood</i> , 2006 , 108, 1652-60	2.2	362
149	New mutations and pathogenesis of myeloproliferative neoplasms. <i>Blood</i> , 2011 , 118, 1723-35	2.2	316
148	Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. <i>Blood</i> , 2017 , 129, 667-679	2.2	275
147	Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. <i>Journal of Clinical Oncology</i> , 2011 , 29, 573-82	2.2	238
146	TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). <i>Blood</i> , 2009 , 114, 3285-91	2.2	231
145	Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. <i>Blood</i> , 2010 , 115, 2891-900	2.2	224
144	Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. <i>Blood</i> , 2016 , 127, 1325-35	2.2	204
143	High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. <i>Blood</i> , 2006 , 108, 2037-40	2.2	200
142	TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. <i>Haematologica</i> , 2009 , 94, 1676-81	6.6	198
141	High Thrombopoietin Production by Hematopoietic Cells Induces a Fatal Myeloproliferative Syndrome in Mice. <i>Blood</i> , 1997 , 90, 4369-4383	2.2	196
140	Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. <i>Blood</i> , 2006 , 108, 346-52	2.2	195
139	Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. <i>Blood</i> , 2002 , 100, 3495-503	2.2	192
138	Clonal architecture of chronic myelomonocytic leukemias. <i>Blood</i> , 2013 , 121, 2186-98	2.2	189

137	Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. <i>Blood</i> , 2016 , 127, 1317-24	2.2	178
136	Acquired initiating mutations in early hematopoietic cells of CLL patients. <i>Cancer Discovery</i> , 2014 , 4, 1088-1091	1.0	172
135	Deficiency in the Wiskott-Aldrich protein induces premature proplatelet formation and platelet production in the bone marrow compartment. <i>Blood</i> , 2006 , 108, 134-40	2.2	155
134	The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. <i>Blood</i> , 2007 , 110, 1013-21	2.2	152
133	Endomitosis of Human Megakaryocytes Are Due to Abortive Mitosis. <i>Blood</i> , 1998 , 91, 3711-3723	2.2	147
132	Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho/Rock signaling. <i>Blood</i> , 2008 , 112, 3164-74	2.2	144
131	Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. <i>Nature Communications</i> , 2016 , 7, 10767	17.4	140
130	JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. <i>Blood</i> , 2008 , 112, 1402-12	2.2	140
129	Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. <i>Blood</i> , 2011 , 118, 2551-5	2.2	139
128	Proplatelet formation is regulated by the Rho/ROCK pathway. <i>Blood</i> , 2007 , 109, 4229-36	2.2	139
127	JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. <i>Seminars in Cell and Developmental Biology</i> , 2008 , 19, 385-93	7.5	137
126	Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. <i>Blood</i> , 2007 , 109, 71-7	2.2	135
125	FLI1 monoallelic expression combined with its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia. <i>Journal of Clinical Investigation</i> , 2004 , 114, 77-84	15.9	133
124	Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. <i>Blood</i> , 2010 , 116, 783-7	2.2	129
123	Thrombocytopenia resulting from mutations in filamin A can be expressed as an isolated syndrome. <i>Blood</i> , 2011 , 118, 5928-37	2.2	128
122	JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. <i>Journal of Biological Chemistry</i> , 2005 , 280, 41893-9	5.4	128
121	A common bipotent progenitor generates the erythroid and megakaryocyte lineages in embryonic stem cell-derived primitive hematopoiesis. <i>Blood</i> , 2009 , 114, 1506-17	2.2	123
120	Mechanisms of WASp-mediated hematologic and immunologic disease. <i>Blood</i> , 2004 , 104, 3454-62	2.2	122

119	Activating mutations in human acute megakaryoblastic leukemia. <i>Blood</i> , 2008 , 112, 4220-6	2.2	121
118	Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation. <i>Journal of Clinical Investigation</i> , 2014 , 124, 580-91	15.9	119
117	An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. <i>Blood</i> , 2006 , 107, 1864-71	2.2	115
116	Remodeling of Bone Marrow Hematopoietic Stem Cell Niches Promotes Myeloid Cell Expansion during Premature or Physiological Aging. <i>Cell Stem Cell</i> , 2019 , 25, 407-418.e6	18	114
115	Effects of Cytokines on Platelet Production From Blood and Marrow CD34+ Cells. <i>Blood</i> , 1998 , 91, 830-843		114
114	Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. <i>Blood</i> , 2016 , 127, 333-42	2.2	113
113	RUNX1-induced silencing of non-muscle myosin heavy chain IIB contributes to megakaryocyte polyploidization. <i>Nature Communications</i> , 2012 , 3, 717	17.4	107
112	Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. <i>Blood</i> , 2010 , 116, 1132-5	2.2	105
111	Phenotypic and Functional Evidence for the Expression of CXCR4 Receptor During Megakaryocytopoiesis. <i>Blood</i> , 1999 , 93, 1511-1523	2.2	105
110	Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , 2007 , 109, 2202-4	2.2	103
109	JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN γ . <i>Blood</i> , 2013 , 122, 1464-77	2.2	95
108	Reduced retention of radioprotective hematopoietic cells within the bone marrow microenvironment in CXCR4 $^{-/-}$ chimeric mice. <i>Blood</i> , 2006 , 107, 2243-51	2.2	95
107	The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. <i>Blood</i> , 2008 , 112, 2429-38	2.2	90
106	Interrelation between polyploidization and megakaryocyte differentiation: a gene profiling approach. <i>Blood</i> , 2007 , 109, 3225-34	2.2	85
105	Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. <i>Blood</i> , 2009 , 114, 1628-32	2.2	84
104	Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. <i>Blood</i> , 2007 , 110, 3735-43	2.2	84
103	Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. <i>Nature Genetics</i> , 2015 , 47, 1131-40	36.3	83
102	Differential regulation of actin stress fiber assembly and proplatelet formation by α 2 β 1 integrin and GPVI in human megakaryocytes. <i>Blood</i> , 2004 , 104, 3117-25	2.2	83

101	JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. <i>F1000Research</i> , 2018 , 7, 82	3.6	83
100	Genetic basis of congenital erythrocytosis: mutation update and online databases. <i>Human Mutation</i> , 2014 , 35, 15-26	4.7	82
99	A nonsynonymous SNP in the ITGB3 gene disrupts the conserved membrane-proximal cytoplasmic salt bridge in the alphaIIb beta3 integrin and cosegregates dominantly with abnormal proplatelet formation and macrothrombocytopenia. <i>Blood</i> , 2008 , 111, 3407-14	2.2	81
98	RGS16 is a negative regulator of SDF-1-CXCR4 signaling in megakaryocytes. <i>Blood</i> , 2005 , 106, 2962-8	2.2	80
97	The Thrombocytopenia of Wiskott Aldrich Syndrome Is Not Related to a Defect in Proplatelet Formation. <i>Blood</i> , 1999 , 94, 509-518	2.2	79
96	Mammalian target of rapamycin (mTOR) regulates both proliferation of megakaryocyte progenitors and late stages of megakaryocyte differentiation. <i>Blood</i> , 2006 , 107, 2303-10	2.2	76
95	Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression. <i>Blood</i> , 2012 , 120, 2708-18	2.2	75
94	The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. <i>Journal of Clinical Investigation</i> , 2009 , 119, 852-64 ¹⁵⁻⁹		75
93	A senescence-like cell-cycle arrest occurs during megakaryocytic maturation: implications for physiological and pathological megakaryocytic proliferation. <i>PLoS Biology</i> , 2010 , 8, e1000476	9.7	73
92	Megakaryocyte polyploidization is associated with a functional gene amplification. <i>Blood</i> , 2003 , 101, 541-4	2.2	70
91	Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia. <i>Blood</i> , 2015 , 125, 930-40	2.2	66
90	An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. <i>Journal of Experimental Medicine</i> , 2009 , 206, 1701-7	16.6	66
89	MAL/SRF complex is involved in platelet formation and megakaryocyte migration by regulating MYL9 (MLC2) and MMP9. <i>Blood</i> , 2009 , 114, 4221-32	2.2	63
88	The SCL relative LYL-1 is required for fetal and adult hematopoietic stem cell function and B-cell differentiation. <i>Blood</i> , 2006 , 107, 4678-86	2.2	63
87	MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations. <i>Blood</i> , 2012 , 120, 2719-22	2.2	61
86	Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. <i>Blood</i> , 2014 , 123, 1372-83	2.2	59
85	A new form of macrothrombocytopenia induced by a germ-line mutation in the PRKACG gene. <i>Blood</i> , 2014 , 124, 2554-63	2.2	59
84	Role of p21(Cip1/Waf1) in cell-cycle exit of endomitotic megakaryocytes. <i>Blood</i> , 2001 , 98, 3274-82	2.2	59

83	Orientation-specific signalling by thrombopoietin receptor dimers. <i>EMBO Journal</i> , 2011 , 30, 4398-413	13	57
82	Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. <i>Blood</i> , 2010 , 115, 1037-48	2.2	56
81	The formin DIAPH1 (mDia1) regulates megakaryocyte proplatelet formation by remodeling the actin and microtubule cytoskeletons. <i>Blood</i> , 2014 , 124, 3967-77	2.2	49
80	Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. <i>Journal of Clinical Investigation</i> , 2017 , 127, 1316-1320	15.9	47
79	Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants. <i>Blood</i> , 2019 , 133, 2669-2681	2.2	45
78	Asymmetrical segregation of chromosomes with a normal metaphase/anaphase checkpoint in polyploid megakaryocytes. <i>Blood</i> , 2001 , 97, 2238-47	2.2	45
77	Immunosuppression by Mutated Calreticulin Released from Malignant Cells. <i>Molecular Cell</i> , 2020 , 77, 748-760.e9	17.6	45
76	P19INK4D links endomitotic arrest and megakaryocyte maturation and is regulated by AML-1. <i>Blood</i> , 2008 , 111, 4081-91	2.2	44
75	Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors. <i>Journal of Cellular and Molecular Medicine</i> , 2013 , 17, 1397-409	5.6	43
74	Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia. <i>Blood</i> , 2011 , 118, 6310-20	2.2	43
73	Megakaryocyte and polyploidization. <i>Experimental Hematology</i> , 2018 , 57, 1-13	3.1	42
72	Monocytic cells derived from human embryonic stem cells and fetal liver share common differentiation pathways and homeostatic functions. <i>Blood</i> , 2011 , 117, 3065-75	2.2	41
71	FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis. <i>Cancer Research</i> , 2011 , 71, 2901-15	10.1	39
70	Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. <i>Blood</i> , 2012 , 119, 4625-35	2.2	37
69	A CALR mutation preceding BCR-ABL1 in an atypical myeloproliferative neoplasm. <i>New England Journal of Medicine</i> , 2015 , 372, 688-90	59.2	35
68	JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation. <i>Blood</i> , 2014 , 124, 2104-15	2.2	34
67	Aurora B is dispensable for megakaryocyte polyploidization, but contributes to the endomitotic process. <i>Blood</i> , 2010 , 116, 2345-55	2.2	34
66	TET2 deficiency inhibits mesoderm and hematopoietic differentiation in human embryonic stem cells. <i>Stem Cells</i> , 2014 , 32, 2084-97	5.8	32

65	New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2006 , 32, 341-51	5.3	30
64	Recent advances in understanding myelofibrosis and essential thrombocythemia. <i>F1000Research</i> , 2016 , 5,	3.6	29
63	Critical role of the HDAC6-cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect. <i>Nature Communications</i> , 2017 , 8, 1786	17.4	28
62	A major role of TGF-beta1 in the homing capacities of murine hematopoietic stem cell/progenitors. <i>Blood</i> , 2010 , 116, 1244-53	2.2	27
61	Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy. <i>Blood</i> , 2018 , 132, 4-4	2.2	24
60	Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis. <i>Frontiers in Endocrinology</i> , 2017 , 8, 234	5.7	23
59	Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients. <i>PLoS ONE</i> , 2013 , 8, e74257	3.7	23
58	P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis. <i>Oncotarget</i> , 2016 , 7, 31980-92	3.3	23
57	Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development. <i>Leukemia</i> , 2020 , 34, 510-521	10.7	23
56	CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner. <i>Oncotarget</i> , 2017 , 8, 54082-54095	3.3	22
55	p19 INK4d controls hematopoietic stem cells in a cell-autonomous manner during genotoxic stress and through the microenvironment during aging. <i>Stem Cell Reports</i> , 2014 , 3, 1085-102	8	21
54	Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14 Suppl, S23-35	2	21
53	Concomitant germ-line RUNX1 and acquired ASXL1 mutations in a T-cell acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2013 , 91, 277-9	3.8	21
52	Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines. <i>Blood</i> , 2009 , 114, 1842-51	2.2	21
51	Monocyte/macrophage dysfunctions do not impair the promotion of myelofibrosis by high levels of thrombopoietin. <i>Journal of Immunology</i> , 2006 , 176, 6425-33	5.3	20
50	Disrupted filamin A/Interaction induces macrothrombocytopenia by increasing RhoA activity. <i>Blood</i> , 2019 , 133, 1778-1788	2.2	19
49	Presence of a defect in karyokinesis during megakaryocyte endomitosis. <i>Cell Cycle</i> , 2012 , 11, 4385-9	4.7	18
48	Defective endomitosis during megakaryopoiesis leads to thrombocytopenia in Fanca ^{-/-} mice. <i>Blood</i> , 2014 , 124, 3613-23	2.2	17

47	TET2-mediated 5-hydroxymethylcytosine induces genetic instability and mutagenesis. <i>DNA Repair</i> , 2016 , 43, 78-88	4.3	16
46	Emergence of a BCR-ABL translocation in a patient with the JAK2V617F mutation: evidence for secondary acquisition of BCR-ABL in the JAK2V617F clone. <i>Journal of Clinical Oncology</i> , 2014 , 32, e76-9	2.2	16
45	Identification of R102P Mutation in Hereditary Thrombocytosis. <i>Frontiers in Endocrinology</i> , 2017 , 8, 235	5.7	15
44	The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications. <i>Expert Review of Hematology</i> , 2019 , 12, 437-448	2.8	14
43	Distinct effects of thrombopoietin depending on a threshold level of activated Mpl in BaF-3 cells. <i>Journal of Cell Science</i> , 2002 , 115, 2329-2337	5.3	14
42	Activity of nonmuscle myosin II isoforms determines localization at the cleavage furrow of megakaryocytes. <i>Blood</i> , 2016 , 128, 3137-3145	2.2	14
41	TET2, a tumor suppressor in hematological disorders. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012 , 1825, 173-7	11.2	13
40	An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L. <i>Blood</i> , 2016 , 128, 3146-3158	2.2	13
39	Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells. <i>Blood</i> , 2019 , 134, 2383-2387	2.2	13
38	Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN. <i>Nature Communications</i> , 2020 , 11, 4886	17.4	12
37	Uncoupling of the Hippo and Rho pathways allows megakaryocytes to escape the tetraploid checkpoint. <i>Haematologica</i> , 2016 , 101, 1469-1478	6.6	12
36	Molecular and genetic bases of myeloproliferative disorders: questions and perspectives. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9 Suppl 3, S329-39		11
35	Megakaryocyte polyploidization: role in platelet production. <i>Platelets</i> , 2020 , 31, 707-716	3.6	10
34	New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis. <i>Haematologica</i> , 2018 , 103, 575-586	6.6	9
33	Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T2-ALL and AML-M0. <i>Journal of Cellular and Molecular Medicine</i> , 2017 , 21, 1237-1242	5.6	8
32	Concise Review: Induced Pluripotent Stem Cells as New Model Systems in Oncology. <i>Stem Cells</i> , 2015 , 33, 2887-92	5.8	8
31	Calr Mutants Retroviral Mouse Models Lead to a Myeloproliferative Neoplasm Mimicking an Essential Thrombocythemia Progressing to a Myelofibrosis. <i>Blood</i> , 2014 , 124, 157-157	2.2	8
30	Multilayer intraclonal heterogeneity in chronic myelomonocytic leukemia. <i>Haematologica</i> , 2020 , 105, 112-123	6.6	8

29	Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFN γ in myeloproliferative neoplasms. <i>Blood</i> , 2021 , 138, 2231-2243	2.2	8
28	Regulation of Platelet Production and Life Span: Role of Bcl-xL and Potential Implications for Human Platelet Diseases. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	7
27	A p53-JAK-STAT connection involved in myeloproliferative neoplasm pathogenesis and progression to secondary acute myeloid leukemia. <i>Blood Reviews</i> , 2020 , 42, 100712	11.1	7
26	Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms. <i>Oncogene</i> , 2020 , 39, 5323-5337	9.2	7
25	ATG2B and GSKIP: 2 new genes predisposing to myeloid malignancies. <i>Molecular and Cellular Oncology</i> , 2016 , 3, e1094564	1.2	7
24	JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	7
23	Germline genetic factors in the pathogenesis of myeloproliferative neoplasms. <i>Blood Reviews</i> , 2020 , 42, 100710	11.1	6
22	Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice. <i>Oncogene</i> , 2019 , 38, 1651-1660	9.2	5
21	The Pediatric Acute Leukemia Fusion Oncogene ETO2-GLIS2 Increases Self-Renewal and Alters Differentiation in a Human Induced Pluripotent Stem Cells-Derived Model. <i>HemaSphere</i> , 2020 , 4, e319	0.3	4
20	Functional Consequences of Mutations in Myeloproliferative Neoplasms. <i>HemaSphere</i> , 2021 , 5, e578	0.3	4
19	TET2 haploinsufficiency alters reprogramming into induced pluripotent stem cells. <i>Stem Cell Research</i> , 2020 , 44, 101755	1.6	3
18	Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms. <i>Blood</i> , 2021 , 138, 2142-2148	2.2	3
17	A new efficient tool for non-invasive diagnosis of fetomaternal platelet antigen incompatibility. <i>British Journal of Haematology</i> , 2020 , 190, 787-798	4.5	2
16	CALR mutant protein rescues the response of MPL p.R464G variant associated with CAMT to eltrombopag. <i>Blood</i> , 2021 , 138, 480-485	2.2	2
15	Induced Pluripotent Stem Cells Enable Disease Modeling and Drug Screening in Calreticulin del52 and ins5 Myeloproliferative Neoplasms. <i>HemaSphere</i> , 2021 , 5, e593	0.3	2
14	EZH2: a molecular switch of the MPN phenotype. <i>Blood</i> , 2016 , 127, 3297-8	2.2	2
13	CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients. <i>Haematologica</i> , 2021 , 106, 863-864	6.6	2
12	in acute myeloid leukemia (AML): high prevalence of germline predisposition in French West Indies. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1770-1773	1.9	2

11	TET2 loss, a rescue of JAK2V617F HSCs. <i>Blood</i> , 2015 , 125, 212-3	2.2	1
10	Megakaryocytes tame erythropoiesis with TGF β . <i>Blood</i> , 2020 , 136, 1016-1017	2.2	1
9	Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms. <i>Leukemia</i> , 2021 ,	10.7	1
8	Role of Rho-GTPases in megakaryopoiesis. <i>Small GTPases</i> , 2021 , 12, 399-415	2.7	1
7	Lyl-1 regulates primitive macrophages and microglia development. <i>Communications Biology</i> , 2021 , 4, 1382	6.7	1
6	Macrophage migration inhibitory factor is overproduced through EGR1 in TET2 resting monocytes.. <i>Communications Biology</i> , 2022 , 5, 110	6.7	0
5	Dual role of EZH2 in megakaryocyte differentiation. <i>Blood</i> , 2021 , 138, 1603-1614	2.2	0
4	P53 deletion and NrasG12D cooperate for AML. <i>Blood</i> , 2017 , 129, 271-273	2.2	
3	Myelodysplastic Syndromes: Mechanisms, Diagnosis, and Treatment 2018 , 563-563		
2	JAK/STAT Signalling and Haematological Malignancies 2015 , 1-20		
1	IFN: Jekyll and Hyde. <i>Blood</i> , 2021 , 137, 291-293	2.2	